Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event

This report assesses the observed risk of PML in patients treated with the anti-CD20 monoclonal antibody rituximab in the regulatory authority-approved autoimmune indications rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). This was a cumulative...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Joseph R., Malik, Vineeta, Lacey, Stuart, Brunetta, Paul, Lehane, Patricia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992248/
https://www.ncbi.nlm.nih.gov/pubmed/29508305
http://dx.doi.org/10.1007/s13365-018-0615-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992248/
https://www.ncbi.nlm.nih.gov/pubmed/29508305
http://dx.doi.org/10.1007/s13365-018-0615-7

Ejemplares similares